More than 1,000 genes may serve as possible treatment targets for individuals with kidney disease, according to a new study, ...

These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

A well-known class of drugs used to manage type 2 diabetes and control weight could offer hope for patients who also struggle ...

Sangamo (SGMO) reported positive updated data from a Phase 1/2 study of its gene therapy candidate ST-920 in the treatment of Fabry disease. Read more here.

The global dialysis equipment market is on a strong growth trajectory, with projected sales expected to increase from USD 11,126.0 million in 2024 to an impressive USD 17,780.9 million by 2034. This ...

The global continuous renal replacement therapy market is set for significant expansion, with projections indicating a surge ...

VolitionRx (VNRX) announced the results of a large-scale study which shows that its Nu.Q NETs H3.1 biomarker is an independent predictor of ...

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the results of a large-scale study which shows that its Nu.Q®NETs H3.1 biomarker is an ...

Novo Nordisk has announced that the Food and Drug Administration (FDA) has approved semaglutide (Ozempic) to reduce the risk ...

The Philippine Health Insurance Corporation (PhilHealth) has expanded the Z Benefit package for Peritoneal Dialysis (PD) with ...

Its growth is driven by the rising prevalence of kidney and urological disorders. The global market for nephrology and ...

Pediatric patients can receive P510,000 to P765,210 for CAPD and P763,000 to P1.2 million for APD. The package also includes coverage for related services like infection prevention and treatment for ...